EUVIMEDEUVIMED entdecken
Crossref

Altered Cerebrospinal Fluid Neurofilament Light Chain but Not Neurogranin Levels Are Associated with Response to Ocrelizumab Treatment in Relapsing-Remitting Multiple Sclerosis: A Preliminary Study

Tuğçe Kızılay, Ece Akbayir, Ruziye Erol, Ayça Simay Demir, Duygu Özkan Yaşargün, Vuslat Yilmaz, Erdem Tuzun, Recai Turkoglu

European Neurology · 2024

DOI: 10.1159/000539376 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Neurology, 2024. Verfasst von Tuğçe Kızılay und 7 weiteren Autor:innen. Beteiligte Einrichtung: Neurology Clinic, Haydarpasa Numune Training and Research Hospital, University of Health Sciences, Istanbul, Turkey. Hauptthemen laut MEDLINE: Multiple Sclerosis, Relapsing-Remitting, Antibodies, Monoclonal, Humanized, Neurofilament Proteins, Neurogranin. Die Arbeit nennt 13 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Ocrelizumab is a CD20-targeting monoclonal antibody used for treatment of multiple sclerosis (MS). Serum and cerebrospinal fluid (CSF) neurofilament light (NFL) chain levels are reduced in MS patients under ocrelizumab treatment indicating a preventive action against neuro-axonal degeneration. Our aim, in this preliminary study, was to explore the impact of ocrelizumab treatment on synaptic integrity through assessment of neurogranin levels.

Methods

Thirteen relapsing-remitting multiple sclerosis (RRMS) patients resistant to first-line immunomodulating agents were enrolled and followed up for 24 months under ocrelizumab treatment. Disease activity was monitored by periodic EDSS, MSSS, and cranial-spinal MRI assessments. No evidence of disease activity (NEDA)-3 was determined, and CSF levels of NFL (marker of neuro-axonal integrity) and neurogranin (marker of synaptic integrity) were measured by ELISA at baseline and 12-month ocrelizumab treatment.

Results

Seven RRMS patients, who preserved NEDA-3 status during 24-month follow-up, showed ≥30% NFL level decrease, whereas 6 patients with stable/increased NFL levels displayed relapse, MRI lesion, or disability progression. Although most RRMS patients exhibited increased CSF levels of neurogranin under ocrelizumab treatment, patients with and without neurogranin level increase did not differ in terms of clinical features and NEDA-3 status. Baseline neurogranin levels negatively correlated with baseline EDSS scores.

Conclusion

Our results confirm that NFL effectively monitors treatment response of RRMS patients under ocrelizumab treatment. Neurogranin does not appear to exhibit a similar benefit in screening of RRMS disease activity. Nevertheless, lower neurogranin levels are associated with increased disability in RRMS indicating a potential disease activity biomarker function.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple Sclerosis, Relapsing-RemittingAntibodies, Monoclonal, HumanizedNeurofilament ProteinsNeurograninImmunologic FactorsHumansFemaleMaleAdultMiddle AgedBiomarkersTreatment OutcomeMagnetic Resonance Imaging

Stichwörter der Autor:innen

DisabilityMultiple sclerosisNeurofilament light chainNeurograninOcrelizumab

Substanzen

Antibodies, Monoclonal, HumanizedNeurofilament ProteinsNeurograninneurofilament protein LImmunologic FactorsocrelizumabBiomarkers

Autor:innen und Institutionen

  • Neurology Clinic, Haydarpasa Numune Training and Research Hospital, University of Health Sciences, Istanbul, Turkey.
  • Department of Neuroscience, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey.

Zitieren

APA

Kızılay, T., Akbayir, E., Erol, R., Demir, A. S., Özkan Yaşargün, D., Yilmaz, V., Tuzun, E., & Turkoglu, R. (2024). Altered Cerebrospinal Fluid Neurofilament Light Chain but Not Neurogranin Levels Are Associated with Response to Ocrelizumab Treatment in Relapsing-Remitting Multiple Sclerosis: A Preliminary Study. European Neurology. https://doi.org/10.1159/000539376

Vancouver

Kızılay T, Akbayir E, Erol R, Demir AS, Özkan Yaşargün D, Yilmaz V, et al. Altered Cerebrospinal Fluid Neurofilament Light Chain but Not Neurogranin Levels Are Associated with Response to Ocrelizumab Treatment in Relapsing-Remitting Multiple Sclerosis: A Preliminary Study. European Neurology. 2024. doi:10.1159/000539376

BibTeX
@article{Kzlay2024,
  author = {Kızılay, Tuğçe and Akbayir, Ece and Erol, Ruziye and Demir, Ayça Simay and Özkan Yaşargün, Duygu and Yilmaz, Vuslat and Tuzun, Erdem and Turkoglu, Recai},
  title = {Altered Cerebrospinal Fluid Neurofilament Light Chain but Not Neurogranin Levels Are Associated with Response to Ocrelizumab Treatment in Relapsing-Remitting Multiple Sclerosis: A Preliminary Study},
  journal = {European Neurology},
  year = {2024},
  doi = {10.1159/000539376}
}
Kostenlos starten →